AstraZeneca’s Diabetes Combo Could Help Stake Its Independence From Pfizer
This article was originally published in The Pink Sheet Daily
Positive trial results buoy the British pharma’s late-stage pipeline as it battles to keep its independence from Pfizer. The saxagliptin/dapagliflozin combo is a cornerstone of the diabetes franchise.
You may also be interested in...
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.